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ABSTRACT  
Objective: To study retention in care (RIC) trajectories and associated factors in patients 
eligible for antiretroviral treatment (ART) in a universal test-and-treat setting (TasP trial, South 
Africa, 2012-2016).  
Design: A cluster-randomized trial whereby individuals identified HIV-positive after home-
based testing were invited to initiate ART immediately (intervention) or following national 
guidelines (control). 
Methods: Exiting care was defined as ≥3 months late for a clinic appointment, transferring 
elsewhere, or death. Group-Based Trajectory Modelling was performed to estimate RIC 
trajectories over 18 months and associated factors in 777 ART-eligible patients.  
Results: Four RIC trajectory groups were identified: i) group 1 “remained” in care (reference, 
n=554, 71.3%), ii) group 2 exited care then “returned” after (median [interquartile range]) 4 [3-
9] months (n=40, 5.2%), iii) group 3 “exited care rapidly” (after 4 [4-6] months, n=98, 12.6%), 
iv) group 4 “exited care later” (after 11 [9-13] months, n=85, 10.9%). Group 2 patients were 
less likely to have initiated ART within 1 month and more likely to be male, young (<29 years), 
without a regular partner and to have a CD4 count >350 cells/mm3. Group 3 patients were more 
likely to be women without social support, newly diagnosed, young, and less likely to have 
initiated ART within 1 month. Group 4 patients were more likely to be newly diagnosed and 
aged ≤39 years.  
Conclusions: High CD4 counts at care initiation were not associated with a higher risk of 
exiting care. Prompt ART initiation and special support for young and newly diagnosed HIV-
patients are needed to maximize RIC. 
Keywords: universal test and treat, HIV, South Africa, retention in care, trajectories 
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INTRODUCTION  
South Africa has the highest number of people living with HIV (PLWHIV) in the world, 
estimated at 7 million in 2015 (1). Forty-nine percent receive antiretroviral therapy 
(ART), making it the largest treatment programme worldwide (2). Despite a reduction 
in HIV-related morbidity and mortality and a consequent increase in life expectancy (3), 
HIV incidence remains unacceptably high (4). 
In 2016, South Africa adopted the WHO’s recommendation to implement a universal 
test-and-treat (UTT) strategy for HIV (4). The success of this strategy depends on 
sustained retention in care (RIC) (5,6). Modelling estimated that in order to achieve an 
HIV incidence rate below 0.1% per year by 2050, rates of ART coverage and RIC need 
to reach 95% (5). 
A meta-analysis in 2015 estimated that RIC among adults who initiated ART in South 
Africa was 77% at 12 months and 75% at 24 months (7). In 2017, the South African 
government set the objective of reaching a retention rate of 90% at 12 months after 
ART initiation among PLWHIV by 2018/19, increasing to 95% by 2021/22 (4). 
In order to achieve this ambitious target, a greater understanding of the barriers to RIC 
in UTT settings, where PLWHIV start treatment early, is needed. To date, literature in 
low- and middle-income countries has mainly focused on non-RIC among pre-ART 
patients (8–10) or patients who start ART with low CD4 counts (≤350 cells/mm3) 
and/or at AIDS stage (11–13). Evidence suggests a lower RIC rate among pre-ART 
patients with high CD4 counts (9,10,14), but it is still unknown whether high CD4 
counts (>350 cells/mm3) at ART initiation will improve or deteriorate RIC. In the only 
study conducted to date in a UTT setting - the SEARCH trial in Uganda and Kenya - the 
authors found high RIC among patients with high CD4 counts (350-500 cells/mm3, and 
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>500 cells/mm3) (15). However, concerns remain that patients with high CD4 counts 
may be more reluctant to engage in treatment (16). Moreover, one limitation of previous 
RIC studies is the assumption that patients follow a single care trajectory while, in 
reality, patients can cycle in and out of care, and so multiple trajectories are possible 
(17,18). 
In this study, we aimed to study RIC trajectories and associated factors in ART-eligible 
patients enrolled in the UTT TASP trial ANRS 12249 implemented in rural South 
Africa.   
 
METHODS  
Study setting and design 
ANRS-12249 TasP (Treatment as Prevention) trial was a cluster-randomized trial 
conducted between 2012-2016 in the Hlabisa sub-district, KwaZulu-Natal, in South-
Africa. The area is mainly rural with scattered homesteads. It is also among the most 
exposed to HIV in the country (19) with an estimated 30% HIV prevalence in adults 
(15-49 years) (20). The main objective of the trial was to investigate whether HIV 
testing of all adult populations followed by immediate ART initiation for all those 
testing positive (irrespective of immunological status or clinical stage) would reduce 
HIV incidence in this area. 
The trial protocol is described elsewhere (21,22). Briefly, it was implemented in 22 (11 
intervention and 11 control) geographic clusters, each with an average population of 
1000 residents ≥16 years. In all clusters, home-based counselling and HIV testing 
(HBCT) were offered every six months to all eligible household members, i.e. residents 
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≥16 years. Individuals testing HIV-positive were then referred to their cluster trial 
clinic. These clinics which were set up specifically for the trial, were located <5 km 
from their homes. The clinics in the intervention clusters immediately offered ART to 
all PLWHIV regardless of CD4 count or clinical stage. Instead, PLWHIV in the control 
clinics initiated ART according the eligibility criteria defined by national guidelines: 
CD4 count ≤350 cells/mm3, WHO stage 3/4, and/or pregnancy (23). In January 2015, 
these criteria were extended to include CD4 count ≤500 cells/mm3, hepatitis B positivity 
and HIV-negative partners in serodiscordant relationships (24). In all the trial clinics, 
patients who initiated ART had monthly clinical follow-up visits, while pre-ART 
patients had a quarterly clinical follow-up. All patients, whether pre-ART or ART-
treated, who were more than three months late for an appointment in their clinic, were 
contacted by phone or during home-based visits. HIV care was also available in 
government clinics located in the trial area which also provided care to non-HIV 
patients (25). Upon request, participants could transfer out from trial care to one of these 
clinics, in or outside the trial area.  
The Biomedical Research Ethics Committee (BREC) of KwaZulu-Natal University 
(BFC 104/11) and the South African Medicines Control Council approved the trial. All 
participants provided written informed consent.  
Outcome 
The study outcome was a time-varying binary variable “retention in trial care” (RIC) 
status, describing whether a patient remained or not in trial care during the 18-month 
study period. A patient was considered to have exited trial care if s/he was >3 months 
late for his/her last appointment at the clinic, if s/he transferred out or if s/he died. RIC 
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status in the trial clinics was assessed for each patient every month from 4 to 18 months 
after his/her baseline visit (RIC status was therefore not defined during the first four 
months of follow-up). A patient lost to follow-up (LTFU) at a given month could re-
enter trial care if s/he revisited a trial clinic later. 
Study population and study period 
The study population included HIV-positive individuals eligible to initiate ART (as per 
the trial protocol) at their first visit in one of the trial’s clinics (baseline visit), who had 
their baseline visit ≥18 months before the end of the trial (30th June 2016), and who did 
not die in the first 4 months of follow-up. The study period covered from 4 to 18 
months after the baseline visit of each patient. 
Covariates 
Information on covariates used in the analysis was obtained from (i) face-to-face 
questionnaires administered during home-based visits and at baseline visit in clinics, 
and (ii) clinical report forms completed by caregivers at baseline and during follow-up.  
Covariate information collected during home-based visits included gender, age, 
education, having children, occupation, household wealth, and geographical 
accessibility to the trial’s clinics. Covariates collected at the baseline clinic visit 
included CD4 count, having a regular partner, social support, psychological distress 
(Patient Health Questionnaire-4 scale (26)), time between referral and baseline visit, and 
being newly diagnosed at referral (i.e., reporting - during HBHT - no previous HIV-
positive diagnosis and not being registered as a HIV patient in local government 
clinics). We also distinguished patients who initiated ART within one month after 
baseline from those who did not. Finally, we classified the 22 clusters into a binary 
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variable: (i) clusters with low number of patients (13-155) followed in the trial’s clinics 
(HIV prevalence in those clusters was 17.5%-35.4%), (ii) clusters with high number of 
patients (212-422) followed in the trial’s clinics (HIV prevalence: 32.3-39.4%).  
Statistical analysis 
Group-Based Trajectory Modelling (GBTM) was performed to estimate RIC trajectories 
during the study period using the outcome variable “retention in trial care”. GBTM is a 
semi-parametric mixture modelling procedure for longitudinal data (27), which 
identifies trajectory groups over time. It classifies individuals into groups with similar 
evolution for the outcome variable, and identifies factors associated with these groups.  
The optimal number of trajectory groups was evaluated using the Bayesian Information 
Criterion (BIC), by selecting the number of groups that best represented the 
heterogeneity between the trajectories.  
The probabilities of group membership were estimated using a multinomial logistic 
model. Patients were assigned to the group for which they had the highest estimated 
probability of membership. Each identified group had a specific trajectory that 
illustrated the probabilities of having exited care at a given month from 4 to 18 months 
after baseline. We assumed that the probability of exiting care followed a binary logit 
distribution. 
Factors associated with trajectory group membership were tested for in the analysis as 
fixed covariates measured at the baseline visit and at one month after baseline for the 
ART initiation covariate. The model parameters were estimated using the maximum 
likelihood method.  
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Covariates were considered eligible for the GBTM multivariable model if their 
association with group membership indicated a p-value <0.20 in GBTM univariable 
analyses. A forward stepwise procedure was used to select the covariates in the final 
multivariable model with a p-value ≤0.05.  
All analyses were performed using Stata/SE 12.1 for Windows software (28). 
Sensitivity analysis 
Sensitivity analysis were conducted to assess the robustness of the results when 
considering the following: i) a longer follow-up period (i.e. from 4 to 24 months after 
baseline), ii) alternative hypotheses for transfers-out. Specifically, we considered 
transfers-out as missing data from the time the patients transferred out (accordingly, 
exiting trial care only included deaths and LTFU). Second, we assessed an optimistic 
but realistic scenario where transfers-out were considered to be “retained in care”. 
 
RESULTS  
Cohort profile 
Of the 7647 PLWHIV who were referred to the trial clinics over the trial period, 3019 
(39.5%) actually visited a trial clinic at least once. Among these, 1412 (46.8%) were 
already on ART at the baseline visit, 428 (14.2%) were not eligible for ART, and 16 
(0.5%) had missing data for either ART status or CD4 cell count. Of the remaining 1163 
(38.5%) individuals - all eligible to initiate ART at baseline - we retained those who had 
their first visit ≥18 months before the end of the trial (788 patients), and excluded those 
who died during the first four months of follow-up (10 patients) since retention was not 
defined during this period, as well as one patient whose recorded date of death was 
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inconsistent. Our study population therefore comprised 777 ART-eligible patients 
(Supplementary Figure 1, http://links.lww.com/QAI/B264).  
Approximately two-thirds (70.7%) of our study population were women (Table 1). The 
median age [interquartile range (IQR)] at baseline was 35 [27.5; 46.6] years, and 76.2% 
had a regular partner. Most patients (88.5%) were already diagnosed HIV-positive at 
referral. Two-thirds (66.3%) entered HIV care at one of the trial’s clinics within one 
month after referral and 40% resided <1 km from their clinic. Over a quarter (26.3%) of 
patients had a CD4 count >500 cells/mm3 at baseline and 54% initiated ART within one 
month.  
Retention in care and retention trajectories 
The overall RIC rate was 77.5% at 12 months (M12) and 72.8% at M18 (Figure 1a). 
Among patients exiting trial care, LTFU was the main cause of attrition (76.6% and 
73.4% at M12 and M18, respectively), while death accounted for 6.9% and 8.1%, 
respectively, and transfers-out for 16.6% and 18.5%. The median [IQR] follow-up 
duration before exiting care for the first time was 7 [4; 11] months.  
RIC rates at M18 were similar in both arms (70.8% - control versus 73.8% - 
intervention, p=0.37), and between the three different CD4 count categories (71.9%, 
77.8% and 69.6% for CD4 counts ≤350 cells/mm3, 350-500 cells/mm3, and >500 
cells/mm3, respectively; p=0.22). In addition, focusing only on the 704 (90.6%) patients 
who initiated ART over the study period, the RIC rate at M18 reached 80.0% (79.4% - 
control versus 80.3% - intervention, p=0.79). 
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Four different trajectories were identified (Figure 2). Group 1 patients (71.3% of the 
study population) “remained in care” throughout the study period. At M18, fewer than 
1% of them had died or transferred out (Figure 1b). Group 2 patients (5.2%) exited care 
and then returned later, after a median time [IQR] of 4 [3-9] months (hereafter the 
“returned” group). At M18, no deaths had occurred in this group and only one patient 
(2.5%) had transferred out. Group 3 patients (12.6%) “rapidly exited” care after a 
median time [IQR] of 4 [4-6] months of follow-up. In this group, all patients had exited 
trial care at M18 (8.2% had died and 21.4% had transferred out). Finally, Group 4 
patients (10.9%) “exited care later” after a median time [IQR] of 11 [9-13] months of 
follow-up. At M18, 9.4% of them had died while 12.9% had transferred out.  
ART initiation by trajectory group 
While all study patients were ART-eligible at baseline, overall 90.6% initiated ART 
during the study period. Furthermore, ART initiation differed widely across the four 
trajectory groups (Table 2). In Groups 1 and 4, a large majority of patients initiated 
ART during the study period (99.6% and 87.1%, respectively), mainly during the first 
month after baseline. In Group 2, a large majority (85.0%) also initiated ART during the 
study period but after a longer delay (median [IQR] time after baseline: 343 [208-449] 
days). Conversely, in Group 3, only 44.9% initiated ART during the study period but 
within a short delay after baseline (median [IQR] time: 27.5 [15.5-49.5] days).  
Factors associated with trajectory groups  
Table 3 presents the results of the univariable and multivariable analyses.  
In the multivariable model, the patients of Group 2 compared with those in Group 1 
(reference group) were more likely to be young (adjusted odds ratio (aOR) [95% 
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confidence interval (CI)]=3.3 [1.4;8.2] for 16-29 years old versus ≥40 years old), 
without regular partner (2.8 [1.1;6.8]), men receiving social support (3.4 [1.4;8.3] 
versus women receiving social support), and to have high CD4 counts (7.7 [2.6;23.1] 
and 5.1 [1.7;15.4] for CD4 counts between 350-500 cells/mm3 and >500 cells/mm3, 
respectively, versus CD4 counts ≤350 cells/mm3).  
The patients in Group 3, compared with those in Group 1, were significantly younger 
(3.9 [2.1;7.2] for patients aged 16-29 years old versus  ≥40 years old), were more likely 
to be women without social support (2.2 [1.1,4.2] versus women with social support), 
and newly diagnosed (4.2 [2.2;8.2]).  
By contrast, the patients in Group 2 and those in Group 3, compared with those in 
Group 1, were less likely to have initiated ART within 1 month after baseline (0.03 
[0.0;0.2] and 0.2 [0.1;0.3], respectively). 
Finally, the patients in Group 4, compared with those in Group 1, were more likely to be 
young (4.6 [2.3;9.3] for 16-29 years old and 2.7 [1.3;5.7] for 30-39 years old versus ≥40 
years old), and newly diagnosed (5.3 [2.7;10.1]).  
Sensitivity analyses 
When estimating the trajectory groups over a 24-month period (n=536), the retention 
rate decreased to 69.2% at M24 and was similar in both arms (63.9% - control versus 
71.4% - intervention, p=0.09), and between the three CD4 counts categories at baseline 
(69.8%, 74.7% and 65.6% for CD4 counts ≤350 cells/mm3, between 350-500 cells/mm3, 
and >500 cells/mm3, respectively; p=0.311). A similar pattern including four trajectory 
groups was identified, but an additional group of patients (Group 5) who exited care 
after a median [IQR] time of 17 [15-20] months emerged (Supplementary Figure 2, 
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http://links.lww.com/QAI/B264). Group 5 included 41 (7.6%) patients who were all in 
Group 4 of the main analysis (over the 18-month period). The only factor associated 
with Group 5 was being a woman without social support (aOR [95% CI]=2.6 [1.1;6.3] 
versus a woman reporting social support), while associated factors for the four other 
groups were the same as those identified in the main analysis.  
When considering transfers-out as missing data, the retention rate at M12 and M18, 
respectively, increased to 80.5% and 76.7%. We found the same associated factors for 
each group as in the main analysis, except for social support, which was no longer 
significant (Supplementary Table 1, http://links.lww.com/QAI/B264). Similar results 
were found when considering transfers-out as “remaining in care”: the RIC rate at M12 
and M18, respectively, increased to 81.2% and 77.9%, and the same associated factors 
were identified (Supplementary Table 2, http://links.lww.com/QAI/B264).  
DISCUSSION  
This study investigated retention in care among HIV-positive patients in Kwazulu-Natal 
in South Africa, who were eligible for ART in a UTT setting where HIV prevalence 
ranged from 17% in very rural areas to 39% in communities close to the zone’s national 
highway (29). Retention at 18 months was 72.8% overall and 80.6% if we only consider 
patients who initiated ART during the study period. Furthermore, using an original 
approach - group-based trajectory modelling - we identified care trajectories and their 
respective associated factors in this population, which is central for tailoring and 
prioritizing interventions. We showed that patterns of engagement with care are not 
uniform. Although three quarters of the study patients remained in care during the 
whole study period, three trajectories for exiting care emerged. Two corresponded to 
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patients who left care and did not return during the study period (12.6% exited care after 
a very short follow-up duration, while 10.9% left after a longer duration). The third 
trajectory (5.2%) represented patients who exited care relatively rapidly but then 
returned. Our findings also suggest that initiating care in a UTT setting is not associated 
with lower retention, but that patients with high CD4 counts are more likely to exit care 
and then return. In addition, prompt ART initiation (within one month after first visit in 
a trial clinic) was associated with a lower risk of exiting care rapidly and of exiting then 
returning. The main factors associated with care exit trajectories (either rapidly or later) 
included male gender, young age and being newly diagnosed.  
Retention rates found in our study are slightly higher than those estimated for the same 
period among patients initiating ART in South Africa’s national ART programme 
(80.6% versus 71%). Although relatively high, these retention rates are still well below 
95%, the estimated rate needed to ensure the eradication of the HIV epidemic (5) and 
the target set by the 2017-2022 South African National Strategic Plan (4). In addition, 
we found no significant difference in retention rates between the trial’s arms, or the 
CD4 count categories (≤350; 350-500; >500 cells/mm3) at baseline. This was confirmed 
in multivariable analysis where patients with high CD4 counts (350-500 cells/mm3 and 
>500 cells/mm3) were not at higher risk of exiting care (either rapidly or later) than 
those with CD4 counts ≤350 cells/mm3. These findings suggest that initiating ART 
early in UTT settings is not associated with lower retention, probably because 
immediate ART initiation limits the duration of the pre-ART period, when the risk of 
exiting care is the highest (30). However, we showed that patients with high CD4 
counts had a higher risk of exiting care and returning afterwards. In addition, ART 
initiation within 1 month after the first visit to a trial clinic was significantly associated 
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with a lower risk of exiting care rapidly (whether subsequently returning or not), 
suggesting that in a UTT setting, rapid ART initiation fosters retention. Interestingly, in 
the “returned” group, despite relatively high ART uptake over 18 months (85%), almost 
95% of the patients had not initiated ART within 1 month, but did so within 
approximately one year. Delayed ART initiation in those with high CD4 count may be 
due to patients being hesitant to initiate ART rapidly (31), but also due to care providers 
prioritising patients with lower CD4 counts in clinics with high patient loads (32). 
As found in other settings (33,34), retaining young patients in care is a challenge. 
Indeed, young age (<30) was a common risk factor for the three trajectories of care exit. 
It has been shown that this population had more competing life activities preventing 
them from attending clinical appointments on a regular basis (17,31,35). The trial 
setting was also characterised by a high migration level, which may have contributed to 
lower engagement in care by younger individuals who are more mobile (36,37). 
Furthermore, our findings highlight the importance of providing support to newly 
diagnosed HIV-positive individuals and of closely accompanying them on the HIV care 
continuum. Indeed, in the TasP trial, these people were less likely to be linked to care 
(38) and had a higher risk of exiting care. This not only suggests that a long delay is 
required to first accept the disease, and to decide whether or not to attend a clinic, but 
also that newly diagnosed persons who attend a clinic may not be ready to engage 
steadfastly in care. Although such difficulties are not specific to the UTT strategy 
(39,40), they may be more frequent in this setting as this strategy does not rely on a 
voluntary testing initiative, and therefore people may be less psychologically prepared 
to receive a positive diagnosis. 
AC
CE
PT
ED
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. 
16 
 
In this rural area of Kwazulu-Natal in South Africa, where HIV prevalence has reached 
extremely high levels, interventions are urgently needed to accelerate access to ART 
and to optimize retention in care, with the goal of achieving viral suppression in 
PLWHIV and reducing new infection incidence in the community. Prompt and early 
ART initiation proposed in a UTT setting may be an effective means to reach this 
objective. In the TasP trial, most of PLWHIV who initiated ART within one month had 
only one visit in a trial clinic before ART initiation. However, a non-negligible 
proportion of our study population (7.2%) never returned after their first visit, and a 
significant proportion of those who exited care during the study period (30.6%) attended 
clinics only once. Considering the importance of the first visit for future retention, a 
great deal of attention should be paid to patients during this visit, in order to adequately 
prepare them for ART initiation. Special attention is needed for the youngest, those 
newly diagnosed, and those with high CD4 counts who may be more hesitant to engage 
steadfastly in care and may require additional visits before initiating ART. Home-based 
ART initiation is another potential intervention which may encourage rapid ART 
initiation if patients are adequately prepared (41). 
Our study has limitations. First, we focused on RIC only in the trial’s clinics because we 
lacked information about the retention status of patients who transferred out to public or 
private facilities. The latter were assumed to have exited care, which may have led to an 
underestimation of the retention rate. However, sensitivity analyses showed that our 
results are robust when considering alternative hypotheses for transfers-out. Second, 
although a tracking team contacted patients LTFU either by phone or during home-
based visits, a certain number of silent transfers may have occurred, contributing to an 
underestimation of the retention rate. This limitation has often been mentioned in other 
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studies (42,43). Third, although the TasP trial has been implemented at the population 
level with HIV status ascertained for 83% of adults living in the trial area (29), only 
39.5% (3019/7647) of HIV-positive individuals referred for HIV care during HBHT 
actually attended a trial clinic. However, a significant proportion (42.7%) of the 7647 
participants were already in the care of government clinics. Most of the latter 
(approximately 95%) were already ART-treated and thus not eligible for our study. In 
addition, according to a previous study on linkage to care in the trial, the majority (i.e. 
approximately 72%) of HIV-positive individuals not in care at referral were not linked 
to care at 3 months (either in TasP or in government clinics), while those linked to care 
attended the trial’s clinics and not the government clinics (44). This suggests that 
selection bias is possible but should be limited as the large majority (i.e. 86%) of our 
target population (HIV-positive individuals who initiated care i.e., who were not already 
being treated) were included in the trial’s clinics.  
 
Despite these limitations, this study brings great added value to current knowledge 
about RIC in the context of UTT strategies in Sub-Saharan Africa. Our approach to 
analysing retention in care is innovative and promising, as it does not consider retention 
as a simple binary variable at a given point of time, rather a dynamic phenomenon 
where patients can cycle in and out of care, with multiple possible trajectories. It 
highlights the different trajectories of disengagement from care, and suggests that 
initiating care in a UTT setting is not associated with lower retention.  
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Our findings may also inform policy makers’ decision on the strategies to improve RIC 
which is crucial for maximizing the impact of ART on the reduction of incidence. This 
includes ensuring prompt ART initiation, and targeting young, newly diagnosed patients 
and those with high CD4 counts, in particular during initial follow-up visits. 
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Figure 1: Retention in care status of ART-eligible patients at first clinic visit from 4 to 
18 months of clinical follow-up, overall (Figure 1a) and according to trajectory group 
(Figure 1b) (ANRS 12249 TasP trial, n=777) 
 
Figure 2: Care trajectories in trial clinics over 18 months of clinical follow-up among 
patients eligible for ART initiation at the first visit (ANRS 12249 TasP trial, n=777) 
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Table 1: Descriptive statistics of the study population at first visit according to trajectory 
groups (ANRS 12249 TasP trial, n=777) 
  Trajectory  groups 
 
Total at first 
visit 
n=777 
Group 1: 
remained in 
care n=554 
(71.3%) 
Group 2: 
exited care 
then returned 
n=40 (5.2%) 
Group 3: 
exited care 
rapidly 
n=98 (12.6%) 
Group 4: 
exited care 
later 
n=85 (10.9%) 
Socio-demographic characteristics, n (%)       
Gender      
Male 228 (29.3) 144 (26.0) 18 (45.0) 31 (31.6) 35 (41.2) 
Female 549 (70.7) 410 (74.0) 22 (55.0) 67 (68.4) 50 (58.8) 
Age, median [IQR] years 
35.0 
[27.5-46.6] 
36.8  
[28.5-49.1] 
30.1  
[26.9-45.7] 
29.8  
[24.9-41.7] 
30.2  
[25.7-37.9] 
Age (years)      
16-29 278 (35.8) 165 (29.8) 19 (47.5) 52 (53.1) 42 (49.4) 
30-39 210 (27.0) 158 (28.6) 7 (17.5) 19 (19.4) 26 (30.6) 
≥40 288 (37.1) 230 (41.6) 14 (35.0) 27 (27.6) 17 (20.0) 
Missing 1 (0.1)     
Educational level      
                     Primary or less 340 (43.8) 256 (46.3) 19 (47.5) 37 (37.8) 28 (33.7) 
Some secondary 281 (36.2) 194 (35.1) 14 (35.0) 42 (42.9) 31 (37.4) 
                      Completed secondary 153 (19.7) 103 (18.6) 7 (17.5) 19 (19.4) 24 (28.9) 
Missing 3 (0.4)     
Had a regular partner      
Yes 592 (76.2) 424 (77.5) 28 (70.0) 70 (76.1) 70 (83.3) 
No 171 (22.0) 123 (22.5) 12 (30.0) 22 (23.9) 14 (16.7) 
Missing 14 (1.8)     
Partner HIV status      
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Partner HIV+ 236 (30.4) 179 (36.3) 13 (33.3) 19 (23.2) 25 (32.5) 
Partner HIV- 71 (9.1) 53 (10.8) 2 (5.1) 7 (8.5) 9 (11.7) 
Do not know 213 (27.4) 138 (28.0) 12 (30.8) 34 (41.5) 29 (37.7) 
No partner 171 (22.0) 123 (25.0) 12 (30.8) 22 (26.8) 14 (18.2) 
Missing 86 (11.1)     
Had children      
Yes 675 (86.9) 493 (91.1) 33 (82.5) 78 (81.3) 71 (86.6) 
No 84 (10.8) 48 (8.9) 7 (17.5) 18 (18.7) 11 (13.4) 
Missing 18 (2.3)     
Economic characteristics, n (%)      
Household wealth index§      
Low  317 (40.8) 225 (40.8) 16 (41.0) 44 (44.9) 32 (38.1) 
Middle  308 (39.6) 218 (39.6) 19 (48.7) 37 (37.8) 34 (40.5) 
High  147 (18.9) 108 (19.6) 4 (10.3) 17 (17.4) 18 (21.4) 
Missing 5 (0.6)     
Occupational status       
Employed 111 (14.3) 90 (16.5) 3 (7.7) 8 (8.3) 10 (12.1) 
Seeking employment 221 (28.4) 149 (27.3) 12 (30.8) 30 (30.9) 30 (36.1) 
Other, inactive 433 (55.7) 307 (56.2) 24 (61.5) 59 (60.8) 43 (51.8) 
Missing 12 (1.5)     
Psychosocial variables, n (%)      
Social support      
Yes 582 (74.9) 423 (78.3) 29 (72.5) 61 (67.0) 69 (82.1) 
No 173 (22.3) 117 (21.7) 11 (27.5) 30 (33.0) 15 (17.9) 
Missing 22 (2.8)     
Gender & Social support      
Female & social support 423 (54.4) 320 (59.3) 15 (37.5) 44 (48.4) 44 (52.4) 
Female & no social support 116 (14.9) 82 (15.2) 7 (17.5) 21 (23.1) 6 (7.1) 
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Male & social support 159 (20.5) 103 (19.1) 14 (35.0) 17 (18.7) 25 (29.8) 
Male & no social support 57 (7.3) 35 (6.5) 4 (10.0) 9 (9.9) 9 (10.7) 
Missing 22 (2.8)     
PHQ-4 depression score      
Not depressed 557 (71.7) 398 (73.2) 33 (84.6) 67 (72.8) 59 (70.2) 
Depressed 202 (26.0) 146 (26.8) 6 (15.4) 25 (27.2) 25 (29.8) 
Missing 18 (2.3)     
Clinical variables, n (%)      
On ART at M1      
No 357 (46.0) 210 (37.9) 38 (95.0) 73 (74.5) 36 (42.4) 
Yes 420 (54.0) 344 (62.1) 2 (5.0) 25 (25.5) 49 (57.6) 
Time between referral and first visit      
Less than 1M 515 (66.3) 368 (66.6) 18 (45.0) 72 (74.2) 57 (67.9) 
1-3M 86 (11.1) 64 (11.6) 7 (17.5) 9 (9.3) 6 (7.1) 
More than 3M 173 (22.3) 121 (21.9) 15 (37.5) 16 (16.5) 21 (25.0) 
Missing 3 (0.4)     
Newly diagnosed at referral      
No 686 (88.3) 518 (93.5) 37 (92.5) 72 (74.2) 59 (70.2) 
Yes 89 (11.5) 36 (6.5) 3 (7.5) 25 (25.8) 25 (29.8) 
Missing 2 (0.3)     
CD4 at first visit      
CD4≤350 405 (52.1) 298 (55.1) 5 (12.8) 51 (52.0) 51 (60.7) 
CD4 between ]350-500] 153 (19.7) 106 (19.6) 17 (43.6) 17 (17.4) 13 (15.5) 
CD4>500  204 (26.3) 137 (25.3) 17 (43.6) 30 (30.6) 20 (23.8) 
Missing 15 (1.9)     
Trial arm      
Control  257 (33.1) 182 (32.9) 13 (32.5) 36 (36.7) 26 (30.6) 
Intervention  520 (66.9) 372 (67.2) 27 (67.5) 62 (63.3) 59 (69.4) 
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Geographic accessibility and clusters, n (%)      
Distance to nearest trial clinic      
≤1 km 311 (40.0) 224 (40.6) 17 (43.6) 38 (38.8) 32 (38.1) 
>1 km 462 (59.5) 328 (59.4) 22 (56.4) 60 (61.2) 52 (61.9) 
Missing 4 (0.5)     
Clusters      
         Clusters with low number of patients and 
HIV prevalence  
349 (44.9) 263 (47.5) 8 (20.0) 40 (40.8) 38 (44.7) 
             Clusters with high number of patients 
and HIV prevalence 
428 (55.1) 291 (52.5) 32 (80.0) 58 (59.2) 47 (55.3) 
IQR: interquartile range 
§
 Household wealth assets were defined in three categories using a principal component analysis on 
sources of energy, amenities and access to drinking water and toilet facilities (45). 
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Table 2: Patients who initiated ART among the study population according to trajectory 
groups (ANRS 12249 TasP trial, n=777) 
n (%) of ART initiation 
within 1 month of 
baseline in TasP clinics 
n (%) of ART initiation 
during the study period 
Median [IQR] days 
between baseline and ART 
initiation 
All 420 (54.1) 704 (90.6) 25 [16-49]  
Group 1: remained in care  344 (62.1) 552 (99.6) 23 [15-42]  
Group 2: exited care then 
returned 
2 (5.0) 34 (85.0) 343.5 [208-449]  
Group 3: exited care 
rapidly 
25 (25.5) 44 (44.9) 27.5 [15.5-49.5]  
Group 4: exited care later 49 (57.7) 74 (87.1) 24 [16-41]  
IQR: interquartile range 
 
 
AC
CE
PT
ED
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. 
6 
 
Table 3: Factors associated with trajectory groups (reference= Group 1: remained in care), univariable and multivariable analyses (ANRS 12249 
TasP trial) 
 
 Univariable analyses 
OR [95% CI] 
 Multivariable analysis 
aOR [95% CI] 
 
 
Covariates 
 Group 2: 
exited care 
then returned 
Group 3: 
exited care 
rapidly 
Group 4: 
exited care 
later 
 Group 2: 
exited care 
then returned 
Group 3: 
exited care 
rapidly 
Group 4: 
exited care 
later 
Gender         
Male  1 1 1  - - - 
Female  2.3* [1.1,4.4] 1.3 [0.8,2.1] 2.0** [1.2,3.2]  - - - 
Age (years)         
≥40   1 1 1  1 1 1 
30-39  0.8 [0.3,1.9] 1.0 [0.5,1.9] 2.2* [1.2,4.4]  1.0 [0.3,2.8] 1.2 [0.6,2.4] 2.7** [1.3,5.7] 
16-29  1.9 [0.9,4.0] 2.7*** [1.6,4.5] 3.5*** [1.9,6.5]  3.3** [1.4,8.2] 3.9*** [2.1,7.2] 4.6*** [2.3,9.3] 
Educational level         
                     Primary or less  1 1 1  - - - 
Some secondary  1.0 [0.5,2.2] 1.5 [0.9,2.4] 1.4 [0.8,2.5]  - - - 
                      Completed secondary  1.0 [0.4,2.4] 1.3 [0.7,2.3] 2.1* [1.1,3.8]  - - - 
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Partner HIV status         
Partner HIV+  1 1 1  - - - 
Partner HIV-  0.5 [0.1,2.4] 1.2 [0.5,3.1] 1.2 [0.5,2.8]  - - - 
Do not know  1.2 [0.5,2.7] 2.3** [1.3,4.3] 1.5 [0.8,2.7]  - - - 
No partner  1.4 [0.6,3.3] 1.7 [0.9,3.3] 0.8 [0.4,1.7]  - - - 
Having a regular partner         
Yes  1 1 1  1 1 1 
No  1.6 [0.8,3.3] 1.1 [0.7,1.8] 0.7 [0.4,1.3]  2.8* [1.1,6.8] 1.5 [0.8,2.8] 1.2 [0.6,2.4] 
Had children         
Yes  1 1 1  - - - 
No  2.0 [0.8,5.0] 2.4** [1.3,4.3] 1.6 [0.8,3.3]  - - - 
Social support         
Yes  1 1 1  - - - 
No  1.3 [0.6,2.9] 1.8* [1.1,2.9] 0.8 [0.4,1.4]  - - - 
Gender & Social support         
Female & social support  1 1 1  1 1 1 
Female & no social support  1.8 [0.7,4.6] 1.9* [1.0,3.3] 0.5 [0.2,1.3]  2.1 [0.7,6.3] 2.2* [1.1,4.2] 0.6 [0.2,1.5] 
Male & social support  2.8* [1.3,6.1] 1.2 [0.7,2.2] 1.8* [1.0,3.0]  3.4** [1.4,8.3] 1.4 [0.7,2.7] 1.7 [0.9,3.1] 
Male & no social support  2.4 [0.7,7.8] 1.9 [0.8,4.2] 1.8 [0.8,4.1]  3.0 [0.8,11.3] 1.6 [0.6,4.0] 1.6 [0.6,4.0] 
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Time between referral and first 
visit 
 
   
 
   
Less than 1M  1 1 1  - - - 
1-3M  2.6 [1.0,7.1] 0.7 [0.3,1.5] 0.6 [0.2,1.4]  - - - 
More than 3M  3.1** [1.4,7.0] 0.7 [0.4,1.2] 1.1 [0.6,1.9]  - - - 
Newly diagnosed at referral         
No  1 1 1  1 1 1 
Yes  1.2 [0.3,4.1] 5.1*** [2.9,9.0] 6.0*** [3.3,10.8]  0.9 [0.2,3.6] 4.2*** [2.2,8.2] 5.3*** [2.7,10.1] 
CD4 at first visit         
CD4≤350  1 1 1  1 1 1 
CD4 between ]350-500]  9.5*** [3.4,26.6] 0.9 [0.5,1.7] 0.7 [0.4,1.4]  7.7*** [2.6,23.1] 0.7 [0.4,1.4] 0.7 [0.3,1.4] 
CD4>500   7.4*** [2.6,20.7] 1.3 [0.8,2.1] 0.9 [0.5,1.5]  5.1** [1.7,15.4] 0.8 [0.4,1.4] 0.8 [0.4,1.5] 
On ART at M1         
No  1 1 1  1 1 1 
Yes  0.02*** [0.0,0.1] 0.2*** [0.1,0.3] 0.8 [0.5,1.3]  0.03*** [0.0,0.2] 0.2*** [0.1,0.3] 0.8 [0.5,1.3] 
Clusters         
Clusters with low number of 
patients and HIV prevalence  
 
1 1 1 
 - - - 
Clusters with high number of  4.0** [1.6,9.7] 1.1 [0.7,1.7] 1.3 [0.8,2.0]  - - - 
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patients and HIV prevalence 
*
 p < 0.05, ** p < 0.01, *** p < 0.001; OR: odds ratio; aOR: adjusted odds ratio, CI: confidence interval 
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Figure 1: Retention in care status of ART-eligible patients at first clinic visit from 4 to 18 
months of clinical follow-up, overall (Figure 1a) and according to trajectory group (Figure 1b) 
(ANRS 12249 TasP trial, n=777) 
Figure 1a: 
 
Figure 1b:
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Figure 2: Care trajectories in trial clinics over 18 months of clinical follow-up among patients 
eligible for ART initiation at the first visit (ANRS 12249 TasP trial, n=777) 
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